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 Psoriasis is an immune-mediated inflammatory skin dis-
ease with a profound impact in patient’s quality of life.1 In 
Portugal, it is estimated that psoriasis affects approximately 
250 000 persons. The understanding of psoriasis’ immuno-
pathogenesis led to the development of biological therapies 
that selectively target disease’s mechanism of action. As in 
other fields of medicine, biological therapies revolutionized 
the treatment of psoriasis, with proven safety and efficacy. 
These agents are an alternative to conventional systemic 
therapies and an important tool at the disposal of dermato-
logist in the management of moderate to severe psoriasis.2 
Currently, it is estimated that approximately 6 000 individu-
als are eligible for the use of biological therapies in Por-
tugal. The available armamentarium includes: Adalimumab 
(Humira®, Abbvie), Etanercept (Enbrel®, Pfizer), Infliximab 
(Remicade®, Janssen Biotech) and Ustekinumab (Stelara®, 
Janssen Biotech).
 The biological therapies, also designated as biologics, 
are proteins derived from living organisms using recombi-
nant DNA technology.3 These products vary in terms of their 
size, structure complexity and immunogenic potential and 
can be identical to molecules produced by the human body, 
such as insulin, growth hormone, erythropoietin and mono-
clonal antibodies that bind to soluble or surface proteins, 
block pathways or cells, or interact with proteins that mimic 
cellular receptors. 
 Unlike chemically synthesized small-molecules, bio-
logics have complex structures of high molecular weight. 
Therefore, slight changes in the production processes may 
lead to differences in the final product.4 Indeed, even diffe-
rent batches of the same product may show a certain level 
heterogeneity.
 The patent expiry of the first generation biologics 
prompted the development of products with a similar struc-
ture as the innovator product, designated as biosimilars, 
aiming to save costs associated with biologics and increase 
patients’ access to therapies that are especially important in 
the treatment of chronic diseases. 
 According to WHO, a biosimilar is a biotherapeutic pro-
duct which is similar (defined as the absence of a relevant 
difference in the parameter of interest) in terms of quality, 
safety and efficacy to an already licensed reference biother-
apeutic product.5 Furthermore, the clinical safety and effi-
cacy was demonstrated by adequate preclinical and clinical 
studies. Biosimilars must ensure similarity with the innova-
tor product regarding some attributes such as the amino 
acid sequence, conformation, post-translational modifica-
tions, immunogenicity, affinity for its ligands and function.
 However, biosimilars are not generics, as the later 
have less complex chemical structures and production pro- 
cesses, being qualitatively and quantitatively equivalent 
to the innovator product in terms of bioavailability and bio-
equivalence.6   
 The manufacturers of the innovator product are not 
required to disclose their manufacturing process after the 
patent expiry. This gap in knowledge increases de probabi-
lity of introducing changes in the manufacturing process of 
biosimilars. In fact, producing an identical copy of a biologic 
is virtually impossible, due to its structural complexity and 
heterogeneity. Therefore, it is probable that these diffe-
rences, especially in the manufacturing process, will lead to 
differences between innovators and biosimilars.7 
 The ability to produce immune responses through the 
development of anti-drug antibodies, known as immunoge-
nicity, extends to all biologics, including biosimilars, and this 
has clinically meaningful implications, especially in terms 
of safety.8 Due to potential structural differences between 
innovators and biosimilars it is possible that the immunoge-
nicity profile can vary between these products.          
 In July 2012, the Korea Food and Drug Administration 
approved CT-P13 (Remsima®, Celltrion), the first biosimi-
lar of a monoclonal antibody (Infliximab, Remicade®, Jans-
sen Biotech). In 2013, EMA approved the use of this bio-
similar in the EU, based on a sole equivalence clinical trial, 
conducted in rheumatoid arthritis patients, supported by a 
pharmacokinetic trial in patients with ankylosing spondylitis. 
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CT-P13 was also granted approval for the other infliximab’s 
indications (Chron’s disease, ulcerative colitis, psoriatic 
arthritis and psoriasis), despite no clinical trials were con-
ducted in these indications.9
 Considering the complexity of biosimilars and all the im-
plications associated with its emergence, it is crucial that 
competent authorities, speciality colleges and scientific so-
cieties disseminate recommendations regarding its use. 
 The authors aim to comment and emphasize the most 
controversial and complex aspects in the context of biosimi-
lars. The authors consider that effective treatments should 
be made available to all patients at the lowest cost possible. 
It is expected that due to the expected cost savings biosimi-
lars will increase the access to biologic therapies. However, 
the highest priority should be given to the patient’s safety, 
so all decision regarding the use of biosimilars and inter-
changeability should be grounded in sound scientific evi-
dence, and follow several guiding principles:
 1. Subtle differences in the production of biologics may 
impact in their functional properties, either in terms of ef-
ficacy or safety. Therefore, for a biologic to be considered 
“similar” to innovator according to the current EU regula-
tory framework it should undergo all pre-clinical and clinical 
steps of the development program.  
 2. The licensing granted for a particular indication 
should not be extrapolated to the innovator’s other indica-
tions without prior minimal efficacy and safety demonstra-
tion in the proposed indications. The potential variability 
between the innovator product and the biosimilar, the dif-
ferent posology regimens, the inherent differences between 
diseases in terms of their physiopathological mechanisms, 
the comorbidities and concomitant therapies, do not ensure 
the same efficacy and safety profile in these different indi-
cations. Thus, the results obtained in rheumatoid arthritis, 
ankylosing spondylitis, inflammatory bowel diseases and 
other indications, should not be extrapolated for psoriasis 
and psoriatic arthritis.
 3. Similarly to the approval process for the innovator 
product in a particular indication, biosimilars should be 
evaluated in clinical trials specifically designed for this same 
indication, since bioequivalence does not necessarily impli-
cate therapeutic equivalence. So, the extrapolation should 
be regarded with caution in the absence of the demonstra-
tion of efficacy through clinical trials, or when safety is not 
completely established.   
 4. Immunogenicity is a primary safety concern of biolog-
ics and can also impact in their efficacy and safety profile. 
Due to the potential variability between the innovator and 
biossimilar, the immunogenic profile can also be different. 
Therefore, the investigation of anti-drug antibodies should 
be a component of clinical trials involving biosimilars.
 5. EMA did not provide any specific guidance regard-
ing interchangeability  (switch from innovator to biosimilar or 
vice-versa according to clinician’s judgment/decision) and 
automatic substitution (switch without the intervention of the 
prescribing clinician), leaving any regulation to the initiative 
of the state members.10 The automatic substitution of an in-
novator for a biosimilar or vice-versa should be considered 
a change of therapeutic and should not be practice without 
the previous knowledge and consent from the prescribing 
clinician or without informing the patients. Furthermore, the 
automatic substitution may compromise the pharmacovigi-
lance programs.   
 6. The biosimilar should have a specific naming proce-
dure in order to distinguish easily between biologics. This 
process will allow the healthcare professionals to accurately 
track the prescribed therapeutic and link the adverse effect 
to a specific product.   
 7. After the licensing of a biosimilar it is essential to 
implement post-marketing surveillance programs to collect 
safety data and detect potentially meaningful rare adverse 
effects.       
 In conclusion, the authors are favorable to the deve-
lopment of biosimilars and their approval from the compe-
tent authorities, provided these products follow the highest 
quality standards in terms of production and development. 
The biosimilars should also undergo a complete efficacy 
and safety evaluation, followed by a post-marketing sur- 
veillance program. The approval of biosimilars in the treat-
ment of psoriasis and psoriatic arthritis should be substan-
tiated by investigation in these populations in order to en-
sure the appropriate efficacy and safety patterns. Clinical 
judgments should be made on an individual basis, based on 
the patient and disease’s circumstances, and always con-
sidering the patient’s safety as the highest priority.   
 Finally, due to the inherent complexity of the biosimilars, 
their potential impact in the patients, clinicians and health-
care system, and in the absence of a regulatory framework, 
the authors emphasize the need of competent authorities, 
Speciality Colleges and scientific societies to generate posi-
tion papers and recommendations regarding the use these 
agents in Portugal.
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